FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382601775> ?p ?o ?g. }

• W4382601775 endingPage "e524" @default.
• W4382601775 startingPage "e515" @default.
• W4382601775 abstract "BackgroundImproved markers for predicting recurrence are needed to stratify patients with localised (stage I–III) renal cell carcinoma after surgery for selection of adjuvant therapy. We developed a novel assay integrating three modalities—clinical, genomic, and histopathological—to improve the predictive accuracy for localised renal cell carcinoma recurrence.MethodsIn this retrospective analysis and validation study, we developed a histopathological whole-slide image (WSI)-based score using deep learning allied to digital scanning of conventional haematoxylin and eosin-stained tumour tissue sections, to predict tumour recurrence in a development dataset of 651 patients with distinctly good or poor disease outcome. The six single nucleotide polymorphism-based score, which was detected in paraffin-embedded tumour tissue samples, and the Leibovich score, which was established using clinicopathological risk factors, were combined with the WSI-based score to construct a multimodal recurrence score in the training dataset of 1125 patients. The multimodal recurrence score was validated in 1625 patients from the independent validation dataset and 418 patients from The Cancer Genome Atlas set. The primary outcome measured was the recurrence-free interval (RFI).FindingsThe multimodal recurrence score had significantly higher predictive accuracy than the three single-modal scores and clinicopathological risk factors, and it precisely predicted the RFI of patients in the training and two validation datasets (areas under the curve at 5 years: 0·825–0·876 vs 0·608–0·793; p<0·05). The RFI of patients with low stage or grade is usually better than that of patients with high stage or grade; however, the RFI in the multimodal recurrence score-defined high-risk stage I and II group was shorter than in the low-risk stage III group (hazard ratio [HR] 4·57, 95% CI 2·49–8·40; p<0·0001), and the RFI of the high-risk grade 1 and 2 group was shorter than in the low-risk grade 3 and 4 group (HR 4·58, 3·19–6·59; p<0·0001).InterpretationOur multimodal recurrence score is a practical and reliable predictor that can add value to the current staging system for predicting localised renal cell carcinoma recurrence after surgery, and this combined approach more precisely informs treatment decisions about adjuvant therapy.FundingNational Natural Science Foundation of China, and National Key Research and Development Program of China." @default.
• W4382601775 created "2023-06-30" @default.
• W4382601775 creator A5003143512 @default.
• W4382601775 creator A5003402829 @default.
• W4382601775 creator A5005839192 @default.
• W4382601775 creator A5009825671 @default.
• W4382601775 creator A5014441086 @default.
• W4382601775 creator A5016212277 @default.
• W4382601775 creator A5018465248 @default.
• W4382601775 creator A5021332651 @default.
• W4382601775 creator A5024124543 @default.
• W4382601775 creator A5036682412 @default.
• W4382601775 creator A5038038681 @default.
• W4382601775 creator A5044797315 @default.
• W4382601775 creator A5051486069 @default.
• W4382601775 creator A5052759245 @default.
• W4382601775 creator A5053797252 @default.
• W4382601775 creator A5054304962 @default.
• W4382601775 creator A5057947122 @default.
• W4382601775 creator A5058598199 @default.
• W4382601775 creator A5062352362 @default.
• W4382601775 creator A5064489084 @default.
• W4382601775 creator A5069146544 @default.
• W4382601775 creator A5072934601 @default.
• W4382601775 creator A5077532887 @default.
• W4382601775 creator A5079206992 @default.
• W4382601775 creator A5080610121 @default.
• W4382601775 creator A5081938339 @default.
• W4382601775 creator A5088408355 @default.
• W4382601775 creator A5090386049 @default.
• W4382601775 creator A5090605165 @default.
• W4382601775 creator A5091360580 @default.
• W4382601775 date "2023-08-01" @default.
• W4382601775 modified "2023-10-09" @default.
• W4382601775 title "Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study" @default.
• W4382601775 cites W1509042831 @default.
• W4382601775 cites W1837902721 @default.
• W4382601775 cites W1975266543 @default.
• W4382601775 cites W2041806580 @default.
• W4382601775 cites W2069480574 @default.
• W4382601775 cites W2078271269 @default.
• W4382601775 cites W2113344831 @default.
• W4382601775 cites W2123664981 @default.
• W4382601775 cites W2152032358 @default.
• W4382601775 cites W2160046825 @default.
• W4382601775 cites W2168403132 @default.
• W4382601775 cites W2190954851 @default.
• W4382601775 cites W2343343747 @default.
• W4382601775 cites W2530419161 @default.
• W4382601775 cites W2573152477 @default.
• W4382601775 cites W2772723798 @default.
• W4382601775 cites W2785961145 @default.
• W4382601775 cites W2914568698 @default.
• W4382601775 cites W2920799158 @default.
• W4382601775 cites W2978882452 @default.
• W4382601775 cites W3004053956 @default.
• W4382601775 cites W3112725886 @default.
• W4382601775 cites W3127892484 @default.
• W4382601775 cites W3196207248 @default.
• W4382601775 cites W4205710681 @default.
• W4382601775 cites W4206841660 @default.
• W4382601775 doi "https://doi.org/10.1016/s2589-7500(23)00095-x" @default.
• W4382601775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37393162" @default.
• W4382601775 hasPublicationYear "2023" @default.
• W4382601775 type Work @default.
• W4382601775 citedByCount "1" @default.
• W4382601775 countsByYear W43826017752023 @default.
• W4382601775 crossrefType "journal-article" @default.
• W4382601775 hasAuthorship W4382601775A5003143512 @default.
• W4382601775 hasAuthorship W4382601775A5003402829 @default.
• W4382601775 hasAuthorship W4382601775A5005839192 @default.
• W4382601775 hasAuthorship W4382601775A5009825671 @default.
• W4382601775 hasAuthorship W4382601775A5014441086 @default.
• W4382601775 hasAuthorship W4382601775A5016212277 @default.
• W4382601775 hasAuthorship W4382601775A5018465248 @default.
• W4382601775 hasAuthorship W4382601775A5021332651 @default.
• W4382601775 hasAuthorship W4382601775A5024124543 @default.
• W4382601775 hasAuthorship W4382601775A5036682412 @default.
• W4382601775 hasAuthorship W4382601775A5038038681 @default.
• W4382601775 hasAuthorship W4382601775A5044797315 @default.
• W4382601775 hasAuthorship W4382601775A5051486069 @default.
• W4382601775 hasAuthorship W4382601775A5052759245 @default.
• W4382601775 hasAuthorship W4382601775A5053797252 @default.
• W4382601775 hasAuthorship W4382601775A5054304962 @default.
• W4382601775 hasAuthorship W4382601775A5057947122 @default.
• W4382601775 hasAuthorship W4382601775A5058598199 @default.
• W4382601775 hasAuthorship W4382601775A5062352362 @default.
• W4382601775 hasAuthorship W4382601775A5064489084 @default.
• W4382601775 hasAuthorship W4382601775A5069146544 @default.
• W4382601775 hasAuthorship W4382601775A5072934601 @default.
• W4382601775 hasAuthorship W4382601775A5077532887 @default.
• W4382601775 hasAuthorship W4382601775A5079206992 @default.
• W4382601775 hasAuthorship W4382601775A5080610121 @default.
• W4382601775 hasAuthorship W4382601775A5081938339 @default.
• W4382601775 hasAuthorship W4382601775A5088408355 @default.
• W4382601775 hasAuthorship W4382601775A5090386049 @default.
• W4382601775 hasAuthorship W4382601775A5090605165 @default.
• W4382601775 hasAuthorship W4382601775A5091360580 @default.

• next